BMC Cancer:按膀胱癌阶段划分的癌症特异性生存以及与生存有关的因素

2021-06-22 AlexYang MedSci原创

膀胱癌是仅次于前列腺癌的第二大泌尿生殖系统癌症。欧洲是膀胱癌发病率最高的地区之一,尤其是意大利和西班牙。根据西班牙癌症登记网络(REDECAN)的数据,如果分开考虑结肠癌和直肠癌,膀胱癌是男性第三大最

膀胱癌是仅次于前列腺癌的第二大泌尿生殖系统癌症。欧洲是膀胱癌发病率最高的地区之一,尤其是意大利和西班牙。根据西班牙癌症登记网络(REDECAN)的数据,如果分开考虑结肠癌和直肠癌,膀胱癌是男性第三大最常见的癌症,女性则是第七大最常见癌症。估计的2019年世界调整后的膀胱癌发病率为男性37.7(95%CI:33.6-42.3)/10万居民,女性7.4(5.6-9.6)。2015年,调整后的死亡率为男性10.46/10万居民,女性1.71/10万居民。

目前,关于膀胱癌各期生存率的信息很少,非浸润性膀胱癌的生存率也是如此。近期,有研究人员调查了膀胱癌按阶段的分布情况;确定了膀胱癌按阶段的癌症特异性生存率;鉴定了解释和预测这些癌症的生存可能性和死亡风险的因素

研究人员通过马洛卡癌症登记处确定了2006年至2011年期间诊断的膀胱癌发病病例。

研究人员收集了以下数据:性别;年龄;诊断日期和方法;根据ICD-O第三版的组织学;诊断时的T、N、M和分期;随访或死亡日期。随访的结束点是2015年12月31日。研究人员进行了多重归因(MI)来评估阶段不明的病例。生存分析中排除了良性或不确定行为的病例。

研究共确定了1914个病例。14%为女性,65.4%为65岁或以上。3.9%没有分期(良性或未确定的行为),11.5%分期不明。在MI之后,37.5%处于Ta期(非浸润性乳头状癌),3.2%处于Tis期(原位癌),34.3%处于I期,11.7%处于II期,4.3%处于III期,9.0%处于IV期。5年后的存活率为76%。各阶段的存活率:Ta期为98%,Tis期为90%,I期为85%,II期为45%,III期为35%,IV期为7%。Cox模型显示,年龄、组织学和阶段(不包括性别)与生存率有关。

膀胱癌患者中按阶段的生存率情况

综上所述,在非浸润性和浸润性病例中,膀胱癌的生存率随阶段变化很大。非浸润性癌症的比例很高。阶段、年龄和组织学均与生存率有关

原始出处:

J Ripoll, M Ramos, J Montaño et al. Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival. BMC Cancer. Jun 2021

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899492, encodeId=bfdb189949293, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 26 09:39:51 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058706, encodeId=ee702058e063e, content=<a href='/topic/show?id=7b99e1413e2' target=_blank style='color:#2F92EE;'>#癌症特异性生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71413, encryptionId=7b99e1413e2, topicName=癌症特异性生存)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 01 08:39:51 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975094, encodeId=396519e5094dc, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Dec 28 20:39:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040036, encodeId=fe6710400365e, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Jun 23 02:39:51 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975983, encodeId=fcc49e5983a9, content=膀胱癌是仅次于前列腺癌的第二大泌尿生殖系统癌症。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Tue Jun 22 23:47:31 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899492, encodeId=bfdb189949293, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 26 09:39:51 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058706, encodeId=ee702058e063e, content=<a href='/topic/show?id=7b99e1413e2' target=_blank style='color:#2F92EE;'>#癌症特异性生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71413, encryptionId=7b99e1413e2, topicName=癌症特异性生存)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 01 08:39:51 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975094, encodeId=396519e5094dc, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Dec 28 20:39:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040036, encodeId=fe6710400365e, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Jun 23 02:39:51 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975983, encodeId=fcc49e5983a9, content=膀胱癌是仅次于前列腺癌的第二大泌尿生殖系统癌症。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Tue Jun 22 23:47:31 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1899492, encodeId=bfdb189949293, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 26 09:39:51 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058706, encodeId=ee702058e063e, content=<a href='/topic/show?id=7b99e1413e2' target=_blank style='color:#2F92EE;'>#癌症特异性生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71413, encryptionId=7b99e1413e2, topicName=癌症特异性生存)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 01 08:39:51 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975094, encodeId=396519e5094dc, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Dec 28 20:39:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040036, encodeId=fe6710400365e, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Jun 23 02:39:51 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975983, encodeId=fcc49e5983a9, content=膀胱癌是仅次于前列腺癌的第二大泌尿生殖系统癌症。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Tue Jun 22 23:47:31 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1899492, encodeId=bfdb189949293, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 26 09:39:51 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058706, encodeId=ee702058e063e, content=<a href='/topic/show?id=7b99e1413e2' target=_blank style='color:#2F92EE;'>#癌症特异性生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71413, encryptionId=7b99e1413e2, topicName=癌症特异性生存)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 01 08:39:51 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975094, encodeId=396519e5094dc, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Dec 28 20:39:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040036, encodeId=fe6710400365e, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Jun 23 02:39:51 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975983, encodeId=fcc49e5983a9, content=膀胱癌是仅次于前列腺癌的第二大泌尿生殖系统癌症。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Tue Jun 22 23:47:31 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
    2021-06-23 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1899492, encodeId=bfdb189949293, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 26 09:39:51 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058706, encodeId=ee702058e063e, content=<a href='/topic/show?id=7b99e1413e2' target=_blank style='color:#2F92EE;'>#癌症特异性生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71413, encryptionId=7b99e1413e2, topicName=癌症特异性生存)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 01 08:39:51 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975094, encodeId=396519e5094dc, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Dec 28 20:39:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040036, encodeId=fe6710400365e, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Jun 23 02:39:51 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975983, encodeId=fcc49e5983a9, content=膀胱癌是仅次于前列腺癌的第二大泌尿生殖系统癌症。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Tue Jun 22 23:47:31 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
    2021-06-22 1453df99m58暂无昵称

    膀胱癌是仅次于前列腺癌的第二大泌尿生殖系统癌症。

    0

相关资讯

Eur Urol Focus:影像组学在预测肌层浸润性膀胱癌中的作用

膀胱癌(BCa)是男性第四大常见癌症,也是第八大致死性癌症。膀胱癌患者的正确分期对治疗决策至关重要。在发达国家,大约75%的BCa患者在诊断时表现为非肌层浸润性BCa(NMIBC),而其余大多数病例表

Eur Urol Oncol:非肌层浸润性膀胱癌患者的长期随访及与主动监测失败相关的因素

近年来,主动监测(AS)在处理一些进展风险较低的泌尿系统肿瘤方面的应用越来越突出。膀胱癌(BC)是男性中第四大常见的癌症,占所有新诊断癌症的7%。低风险非肌层浸润性BC(NMIBC)约占新诊断的BC病

J Urol:根治性膀胱癌切除术后复发尿道癌的风险因素及预后

尿路上皮癌(UC)被归类为一种“场变”疾病,举例:膀胱癌患者治疗后还有发生膀胱外尿路上皮肿瘤的风险,包括上尿路癌症和尿道癌复发。但是,接受根治性膀胱切除术(RC)的患者尿道癌复

Lancet Oncol:派姆单抗单药治疗BCG-无应答性高危型非肌肉浸润性膀胱癌的疗效

派姆单抗单药治疗BCG-无应答性非肌肉浸润性膀胱癌的抗肿瘤活性较高,或可成为这类难以治疗的人群的非手术治疗方案

Eur Urol:抗生素治疗对接受新辅助Pembrolizumab治疗的肌层浸润性膀胱癌患者是否有不利影响?

使用单药免疫检查点抑制剂(ICI)的新辅助免疫治疗(IO)改变了非转移性肌层浸润性膀胱癌(MIBC)围手术期肿瘤治疗的方式。尽管新辅助ICI对大多数膀胱癌组织学类型(包括变异的组织学)是有效的,且不增

Eur Urol Focus:NF Kappa B受体激活剂(RANK)的表达与肌层浸润性膀胱癌患者预后的关系

NF kappa B(RANK)受体激活剂途径在免疫细胞功能、淋巴结发育和骨重塑中发挥着重要作用。此外,该途径是癌症相关骨质变化的关键作用因子之一。在多种实体瘤中,成骨细胞和肿瘤细胞分泌的配体RANK